| Title |
BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study
|
|---|---|
| Published in |
OncoTargets and therapy, February 2017
|
| DOI | 10.2147/ott.s120440 |
| Pubmed ID | |
| Authors |
Allen L Cohn, Bann-Mo Day, Sarang Abhyankar, Edward McKenna, Todd Riehl, Igor Puzanov |
| Abstract |
Mutations in the BRAF gene have been implicated in several human cancers. The objective of this screening study was to identify patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma harboring activating BRAF(V600) mutations for enrollment in a vemurafenib clinical study. Formalin-fixed, paraffin-embedded tumor samples were collected and sent to a central laboratory to identify activating BRAF(V600) mutations by bidirectional direct Sanger sequencing. Overall incidence of BRAF(V600E) mutation in evaluable patients (n=548) was 3% (95% confidence interval [CI], 1.7-4.7): 11% in colorectal tumors (n=75), 6% in biliary tract tumors (n=16), 3% in non-small cell lung cancers (n=71), 2% in other types of solid tumors (n=180), and 3% in multiple myeloma (n=31). There were no BRAF(V600) mutations in this cohort of patients with ovarian tumors (n=68), breast cancer (n=86), or prostate cancer (n=21). This multicenter, national screening study confirms previously reported incidences of BRAF(V600) mutations from single-center studies. Patients identified with BRAF(V600) mutations were potentially eligible for enrollment in the VE-BASKET study. |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 13% |
| Student > Master | 6 | 12% |
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Doctoral Student | 3 | 6% |
| Other | 9 | 17% |
| Unknown | 16 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 31% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Chemistry | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 18 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2020.
All research outputs
#5,176,523
of 25,411,814 outputs
Outputs from OncoTargets and therapy
#253
of 3,019 outputs
Outputs of similar age
#98,261
of 425,035 outputs
Outputs of similar age from OncoTargets and therapy
#11
of 77 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,019 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,035 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.